Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI Blood Loss with Aspirin and Rivaroxaban in Healthy Volunteers
NCT05546957Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of rivaroxaban in thromboembolism (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change from baseline in fecal hemoglobin content at Week 4. Started Jan 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT05546957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546957.